Currently Viewing:
Contributor
CMS Announces Transformative Updates to the MA VBID Model
February 18, 2019
Review Finds VBID Programs Improved Adherence at No Added Cost
August 01, 2018
Value-Based Insurance Design Highlighted at Two Congressional Hearings
July 02, 2018
CMS Rule Creates More Flexibility for Value-Based Benefits in Medicare Advantage
May 25, 2018
High-Deductible Health Plans a Problem for Patients With Cancer
May 10, 2018
Including VBID Principles Can Avoid Negative Effects of Outcomes-Oriented Contracts
April 19, 2018
Legislative Actions Encourage Value in Medicare Advantage and High-Deductible Health Plans
February 23, 2018
Currently Reading
Addressing Rising Cost Sharing With Precision Co-Pay Assistance
February 08, 2018
Study Identifies Unexpected Contributor to Rising Health Costs: Low-Cost Services
December 27, 2017
CMS Expands MA VBID Model Test in 2019
December 08, 2017
CMS Proposed Rule Allows Greater Flexibility for VBID in Medicare Advantage
November 25, 2017
Identifying the Top 5 Low-Value Services That Can Be Targeted for Reduction
November 10, 2017
VBID in Action: Connecticut Health Enhancement Plan
March 26, 2017
Healthcare Stakeholders Call for Flexibility in HSA-HDHPs
March 12, 2017
2016 Year in Review: University of Michigan V-BID Center
February 02, 2017
VBID and Medicare Advantage: Achieving Bipartisan Support
November 30, 2016
Understanding Clinical Nuance
October 25, 2016
Implementing VBID in Medicare and Medicare Advantage
October 19, 2016
The Cost of Low-Value Care
October 11, 2016
Adventures in Healthcare: The Dawn of the High-Value Health Plan
October 04, 2016
Reward the Good Soldier: A Dynamic Approach to Consumer Cost-Sharing for Prescription Drugs
September 26, 2016

Addressing Rising Cost Sharing With Precision Co-Pay Assistance

Since its inception in 2005, the University of Michigan Center for Value-Based Insurance Design (V-BID) has led efforts to promote the development, implementation, and evaluation of innovative health benefit designs balancing cost and quality. A multidisciplinary team of faculty, including A. Mark Fendrick, MD and Michael E. Chernew, PhD, who first published and named the VBID concept, have guided this approach from early principles to widespread adoption in the private and public sectors. The Center has played a key role in the inclusion of VBID in national healthcare reform legislation, as well as in numerous state initiatives. The basic VBID premise is to align patients' out-of-pocket costs, such as copayments, with the value obtained from health services and providers.
This article was collaboratively written by A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design (V-BID), and several V-BID Center staff. 

A new video released by the Center for Value-Based Insurance Design (V-BID) outlines the need for Precision Co-Pay Assistance Programs to address the impacts of increasing consumer cost-sharing and patient assistance programs on appropriate medication utilization.

Consumer cost sharing for medical care and medications is high, and it's getting higher. The average deductible for employer-sponsored single coverage increased by more than 250% between 2006 and 2016, and is now nearly $1500.1 Cost sharing is a useful tool for payers and purchasers to encourage prudent use of healthcare dollars. However, cost sharing has historically been “one-size-fits-all,” and has failed to distinguish between high- and low-value clinical therapies, necessitating a more precise benefit design to enhance patient-centered outcomes, while reducing the harm associated with high cost sharing and finite patient assistance resources.

Cost sharing at high levels is associated with many deleterious consequences. Patients who are subject to greater cost sharing tend to reduce use of services and medications—and the greater the cost share, the greater the corresponding reduction in service use.2-4 This leads to an increased need for third-party assistance to ensure access, including through charitable foundations, co-payment cards, and manufacturer programs.

Patient assistance programs serve to address increasingly salient concerns around cost-related access to clinically indicated prescription medications. However, co-pay cards in particular may undermine reasonable incentives for clinicians and patients to respect plan formularies and speed members toward deductibles and out-of-pocket maximum amounts they might not otherwise satisfy, thereby increasing expenditures and resulting in inefficiencies in the healthcare system. Discount cards usually have a maximum value per fill, so patients who have not yet satisfied a deductible applicable to the pharmacy benefit may still be subject to very high cost sharing. Cards may also have an annual cap on support offered per patient per year.

The use of co-pay assistance for medications for which there is an effective, lower-cost alternative is deemed as financially burdensome to the healthcare system. To counteract this inefficiency, Accumulator Adjuster Programs (AAPs)—which prevent co-pay assistance funds from being applied to patients’ deductibles—are increasingly being implemented, resulting in even greater patient financial responsibility and potential disruption of recommended treatments.  

Precision co-pay assistance programs have the potential to improve prescription affordability while increasing efficiency of limited patient assistance funds. Precision co-pay assistance provides financial assistance exclusively for high-value medications, and is not provided for a drug if there is an effective, lower-cost alternative. This prevents the occurrence of unexpectedly high co-pays for the patient and eliminates the need for AAPs. Both patients and payers benefit from precision assistance programs, as they improve patient outcomes by enhancing access to care and support appropriate medication use.

To learn more about this clinically nuanced solution designed to ensure access to clinically indicated therapies, view the new V-BID Center Precision Co-Pay Assistance video and Precision Patient Assistance brief.

Click to enlarge


References

1. Claxton G, Rae M, Long M, et al. Employer Health Benefits 2016. Kaiser Family Foundation, Health Research & Educational Trust, NORC at the University of Chicago; 2016:274. http://files.kff.org/attachment/Report-Employer-Health-Benefits-2016-Annual-Survey.

2. Newhouse JP, Insurance Experiment Group. Free for All?: Lessons from the RAND Health Insurance Experiment. Cambridge, MA: Harvard University Press; 1996.

3. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69. doi:10.1001/jama.298.1.61.

4. Eaddy MT, Cook CL, O’Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect adherence and outcomes: a literature review. P T Peer-Rev J Formul Manag. 2012;37(1):45-55.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up